Diagnostic standards of von Willebrand disease;Standardisierte diagnostik des von-Willebrand-syndroms

Hamostaseologie

Volumn 24, Issue 1, 2004, Pages 12-26

  Budde, Ulrich ^a   Drewke, E ^a   Will, K ^a   Schneppenheim, R ^b  

^a Labor Prof Arndt and Partner   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Von Willebrand disease; Von Willebrand factor

Indexed keywords

GLYCOPROTEIN; VON WILLEBRAND FACTOR;

BLEEDING; BLEEDING TIME; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; FAMILY HISTORY; GENOTYPE; HEMOSTASIS; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN PROCESSING; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; REVIEW; STANDARD; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; TRANSLATION REGULATION; VON WILLEBRAND DISEASE;

EID: 1242308321     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619602     Document Type: Review

References (45)

1. Allen S, Abuzenadah AM, Blagg JL et al. A novel type 2N von Willebrand disease-causing mutation that results in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95: 2000-7.
2. Bergmann F, Rotmensch S, Rosenzweig B et al. The role of von Willebrand factor in preeclampsia. Thromb Haemost 1991; 66: 525-8.
3. Blombäck M, Eneroth P, Andersson O et al. On laboratory problems in diagnosing mild von Willebrand's disease. Am J Hemat 1992; 40: 117-20.
4. Budde U, Drewke E, Mainusch K et al. Laboratory diagnosis of congenital von Willebrand disease. Sem Thromb Haemost 2002; 28: 173-98.
5. Budde U, Schneppenheim R, Zieger B et al. CBA/VWF: Ag ratio for diagnosis of von Willebrand disease (VWD): incorrect classification in more than 10% of patients with VWD type 2. Thromb Haemost 1999; 100 (Suppl).
6. Budde U, Schneppenheim R. Von Willebrand factor and von Willebrand disease. Rev Clin Exp Hematol 2001; 5: 335-63.
7. Casonato A, Pontara E, Sartorello F et al. Type 2M von Willebrand disease variant characterized by abnormal multimerization. J Lab Clin Med 2001; 137: 70-6.
8. Casonato A, De Marco L, Mazzucato M et al. A new congenital platelet abnormality characterized by spontaneous platelet aggregation, enhanced von Willebrand factor platelet interaction, and the presence of all von Willebrand factor multimers in plasma. Blood 1989; 74: 2028-33.
9. De Marco L, Mazzuccato M, Del Ben MG et al. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors. J Clin Invest 1987; 80: 475-81.
10. Dejana E, Lampugnani MG, Giorgi M et al. Von Willebrand factor promotes endothelial celladhesion via an arg-gly-asp-dependent mechanism. J Cell Biol 1989; 109: 367-75.
11. Dent JA, Berkowitz SD, Ware J et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci U.S.A. 1990; 87: 6306-10.
12. Dong Z, Thoma RS, Crimmins DL et al. Disulfide bonds required to assemble functional von Willebrand factor. J Biol Chem 1994; 269: 6753-8.
13. Furlan M, Robles R, Lämmle P. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
14. Gill JC, Endres-Brooks J, Bauer PJ et al. The effect of AB0 blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
15. Hilbert L, Jenkins PV, Gaucher C et al. Type 2M VWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor. Thromb Haemost 2000; 84: 188-94.
16. Hoyer LW, Shainoff JR. Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980; 55: 1056-9.
17. Hubbard AR, Rigsby P, Barrowcliffe TW. Standardisation of factor VIII and von Willebrand factor in plasma: Calibration of the 4th International Standard (97/586). Thromb Haemost 2001; 85: 634-8.
18. Huizinga EG, van der Plas RM, Kroon J et al. Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. Structure 1997; 5: 1147-56.
19. Jorieux S, Fressinaud E, Goudemand J et al. Conformational changes in the D′ domain of von Willebrand factor induced by CYS25 and CYS95 mutations lead to factor VIII binding defect and multimeric impairment. Blood 2000; 95: 3139-45.
20. Kinoshita S, Harrison J, Lazerson J et al. A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID). Blood 1984; 63: 1369-71.
21. Ledford M, Rabinowtz I, Sadler JE et al. New variant of von Willebrand disease type II with markedly increased levels of von Willebrand factor antigen and dominant mode of inheritance: von Willebrand disease type IIC Miami. Blood 1993; 82: 169-75.
22. Lyons SE, Bruck ME, Bowie EJW et al. Impaired intracellular transport produced by a subset of type-IIA von Willebrand disease mutations. J Biol Chem 1992; 267: 4424-30.
23. Mazurier C, Goudemand J, Hilbert L et al. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Bailliere's Clinical Haematology 2001; 14: 337-47.
24. Nishino M, Girma JP, Rothschild C et al. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-9.
25. Nitu-Whalley IC, Ridell A, Lee CA et al. Identifications of type 2 von Willebrand disease in previously diagnosed type 1 patients: a reappraisal using phenotypes, genotypes and molecular modelling. Thromb Haemost 2000; 84: 998-1004.
26. Plow EF, Srouji AH, Meyer D et al. Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem 1984; 259: 5385-91.
27. Pottinger BE, Read RC, Paleolog EM et al. Von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53: 387-95.
28. Ribba AS, Loisel I, Lavergne JM et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001; 86: 848-54.
29. Rodeghiero F, Castaman GC, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
30. Ruggeri ZM, Nilsson IM, Lombardi R et al. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J Clin Invest 1982; 70: 1124-7.
31. Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease. Characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-25.
32. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987; 328: 491-7.
33. Schneppenheim R, Brassard J, Krey S et al. Defective dimerization of von Willebrand factor subunits due to a Cys Arg mutation in IID von Willebrand disease. Proc Natl Acad Sci USA 1996; 938: 3581-6.
34. Schneppenheim R, Budde U, Obser T et al. Expression and characterization of von Willebrand dimerization defects in different types of von Willebrand disease. Blood 2001; 97: 2059-66.
35. Schneppenheim R, Federici AB, Budde U et al. Von Willebrand disease type 2M »Vicenza« in Italian and German patients: identification of the first candidate mutation (G3864R; R1205H) in 8 families. Thromb Haemost 2000; 83: 136-40.
36. Schneppenheim R, Obser T, Drewke E et al. Isolated molecular defects of von Willebrand factor binding to collagen do not correlate with bleeding symptoms. Blood 2001; 98: 165a.
37. Schneppenheim R, Obser T, Drewke E et al. The first mutations in von Willebrand disease type IIC Miami. Thromb Haemost 2001; (Suppl): P1805.
38. Schneppenheim R, Obser T, Lenk H et al. Characterization of a combined defect of FVIII binding and multimerization in a patient with von Willebrand disease type 2N. Blood 2000; 96: 566a.
39. Schneppenheim R, Obser T, Schneppenheim S et al. Von Willebrand disease type 2A with aberrant structure of individual oligomers is caused by mutations clustering in the von Willebrand factor D3 domain. Blood 2000; 96: 566a.
40. Sixma JJ, De Groot PG. Von Willebrand factor and the blood vessel wall. Mayo Clin Proc 1991; 66: 628-3.
41. Thomas KB, Sutor AH, Zieger B et al. A simple test for the determination of the von Willebrand factor function: The collagen binding activity. Hämostaseologie 1994; 14: 133-9.
42. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is depentent on its confirmation and requires calcium ion. Blood 1996; 87: 4235-44.
43. Zieger B, Budde U, Jessat U et al. New families with von Willebrand disease type 2M (Vicenza). Thromb Res 1997; 87: 57-64.
44. Zimmerman TS, Dent JA, Ruggeri ZM et al. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID and IIE). J Clin Invest 1986; 77: 947-51.
45. Vanhoorelbeke K, Cauwenbergs N, Vauterin S et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-13.